Objective: Epicardial adipose tissue (EAT) is an interesting visceral fat pad with a particular location. EAT and subcutaneous adipose tissue (SAT) produce a wide range of adipokines. Some of them, including adiponectin and leptin, can influence the risk of development of diabetes and other associated metabolic and cardiovascular conditions. We sought to assess whether EAT and SAT adiponectin and leptin expression levels are different in diabetic patients with respect to nondiabetic subjects. Subjects and methods: We collected samples of EAT from 120 patients and samples of SAT from 88 of the same group of patients undergoing elective cardiac surgery for coronary artery bypass grafting (n ¼ 69) or other procedures (n ¼ 51). After RNA isolation, adiponectin and leptin expression levels were analyzed by real-time reverse transcriptase PCR. Plasma levels were determined in small subsamples of subjects. Baseline clinical and treatment data were obtained from medical records. Results: A total of 45 diabetic and 75 nondiabetic subjects were included in the study. Mean (s.d.) age was 70.1 (7.8) years and there were 32% women. EAT and SAT adiponectin and leptin mRNA expression levels were similar in the diabetic and the nondiabetic groups (EAT adiponectin 14.4 (4.3) vs 14.6 (3.4) arbitrary units (a.u.), P ¼ 0.79; SAT adiponectin 15.6 (4.7) vs 15.1 (3.9), P ¼ 0.54; EAT leptin 9.3 (interquartile range 2.5) vs 9.5 (1.9) a.u., P ¼ 0.72; SAT leptin 9.9 (3.6) vs 10.0 (2.5) a.u., P ¼ 0.96). These findings persisted after stratification for sex and coronary artery disease. Logistic regression models including possible confounders and a combination of diabetes and impaired fasting glucose as a dependent variable led to similar results. Plasma adiponectin levels were lower in diabetic patients, whereas leptin levels showed a nonsignificant trend. Conclusion: Diabetic and nondiabetic subjects express similar EAT and SAT adiponectin and leptin levels. Counter-regulatory mechanisms of adiponectin and leptin expression in patients with established diabetes might partly account for these findings.
Introduction
Diabetes is a leading cause of morbidity and mortality and has become a major health issue worldwide. Inflammatory cytokines, such as tumor necrosis factor-a and interleukin-6, have been found to play a relevant role in its physiopathology. 1 Diabetes and metabolic syndrome often present jointly. Adiposity could well be the link between the components of this cluster of pathological conditions. Formerly considered a mere energy depot, adipose tissue has been attributed a most interesting role in the pathogenesis of metabolic and cardiovascular diseases. 2 It produces a large amount of anti-and pro-inflammatory factors generally referred to as adipokines. 3 Classical epidemiological observations found a significant association between visceral adipose tissue--rather than subcutaneous adipose tissue (SAT)--and metabolic and cardiovascular diseases. Thus, the clustering of central obesity with insulin resistance, dyslipidemia and chronic inflammation may account for part of the cardiovascular effects of adiposity. 4 In this line, much attention has been focused on epicardial adipose tissue (EAT), an interesting representative of visceral adipose tissue. EAT extends along the major heart grooves with no anatomical fibrous layer, its products also being able to exert direct effects on the main epicardial coronary arteries and the myocardium. As shown by different groups, EAT expresses a pathogenic profile of adipokines. 2, 5, 6 In recent years, much attention has been focused on adiponectin, the most abundant protein secreted by adipocytes. Initial investigations showed its positive effects as an insulin sensitizer and a protective cardiovascular hormone. 7 Epidemiological and laboratory studies showed a beneficial effect of adiponectin on preventing atherosclerosis and coronary artery disease (CAD). 8 However, more recent research and a comprehensive meta-analysis failed to confirm these findings and led to rather different conclusions, namely that baseline adiponectin circulating levels do not affect the risk of development of CAD significantly. 9 Diabetic patients, especially those with macroangiopathy, have lower adiponectin plasma levels than control subjects. 10 Different studies have shown that lower plasma adiponectin levels are strongly correlated with insulin resistance 11 and predict the development of insulin resistance 12 and diabetes, 11, [13] [14] [15] irrespective of the baseline measures of obesity. Leptin, mainly secreted by adipocytes, 16 is positively correlated to total body fat and has an important role in the regulation of appetite and energy balance. Plasma leptin levels are closely associated with body fat storage and may respond to changes in energy expenditure. Leptin deficiency produces severe obesity and metabolic, immunological and neuroendocrinological dysfunctions. 17 Leptin resistance is far more common and virtually present in all obese subjects. 18 Leptin is associated with insulin resistance 19 and predicts the development of diabetes.
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In vitro research showed that it also exerts some pro-atherosclerotic effects, such as endothelial activation and migration, 21, 22 smooth muscle cell proliferation and calcification, 23 and activation of monocytes. 24 Even though some studies showed an association between high leptin levels and CAD, 25 others failed to do so, 26 despite finding an association between leptinemia and inflammatory markers. 27, 28 The aim of this study is to explore the relationship between EAT and SAT adiponectin and leptin expression and established type 2 diabetes.
Subjects and methods

Subjects
Samples of EAT and SAT were collected from 120 patients (82 men, 38 women) who underwent elective cardiac surgery at our hospital for coronary artery bypass grafting (N ¼ 53), valve surgery (N ¼ 49), both (N ¼ 16), myxoma exeresis (N ¼ 1) or repair of atrial septal defect (N ¼ 1). Exclusion criteria were previous cardiothoracic surgery, infective diseases and type 1 diabetes mellitus, because of its demonstrated different relationship to adiponectin levels. 29 The study was approved by the local institutional review board and conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from every patient before inclusion. The participation rate was 100%.
Clinical data
Clinical data were obtained from medical records. The diagnosis of type 2 diabetes was accurately assessed following the American Diabetes Association current criteria. 30 Patients were classified as diabetic or nondiabetic. Abnormal fasting glucose, as defined by fasting concentrations X5.6 mmol l -1 , was included as a dependent variable in the logistic regression model, together with diabetes. Oral glucose tolerance testing was not routinely applied and thereby impaired glucose tolerance was not ruled out.
Body mass index was calculated from anthropometrical measurements on admission to hospital. Overweight and obesity were defined as body mass index X25 and X30 kg m -2 , respectively.
Blood samples were collected after overnight fasting up to 1 week before surgery and analyzed using standard methods, but cholesterol levels were determined within 6 months before surgery. Significant CAD was discarded or confirmed by noninvasive testing and/or coronary angiogram performed within 6 months before surgery. Cutoff point for angiographically significant coronary artery stenosis was 50% of the lumen diameter.
As regards treatment, we included data concerning the drugs that patients were taking during the weeks immediately before sample collection. Former treatments were not considered.
Collection of adipose tissue samples SAT and EAT samples were obtained before starting extracorporeal circulation. EAT biopsies were harvested from the area close to the proximal tract of the right coronary artery. SAT samples were obtained from the thorax, at the sternotomy incision. All tissue samples were immediately frozen and stored at À80 1C until laboratory processing.
RNA was extracted and purified by the Trizol method. The concentration and purity of the samples were estimated by the ratio between absorbances at 260 and 280 nm. Samples were treated with DNase I to avoid genomic DNA contamination. Each 5 mg of RNA was treated with 10 U of DNase I and 20 U of RNase inhibitor (both manufactured by Invitrogen Ltd, Paisley, UK) for 2 h at 37 1C. Phenol, chloroform and isoamyl alcohol were used to remove proteins and DNA from the samples. RNA was precipitated with 96% ethanol and sodium acetate 0.3 M.
Freezing-thawing cycles were avoided whenever possible to ensure maximum quality of the determinations. The comparative analysis of adiponectin and glyceraldehyde 3-phosphate dehydrogenase expression in EAT was performed with real-time reverse transcriptase PCR using SYBR Green (Roche Diagnostics Corp, Indianapolis, IN, USA) as fluorochrome and the primers previously described. 31 Adiponectin mRNA amplification was performed as follows: 5 min at 95 1C, then 40 cycles of 30 s at 95 1C, 45 s at 60 1C and 60 s at 72 1C. 32 Genomic contamination was ruled out by using negative controls without MMLV at retrotranscription conditions. Fluorescence curves were analyzed with Chromo 4 software (MJ Research, Inc., Reno, NV, USA). Gene expression levels were obtained by calculating the antilogarithm of the inverse adiponectin/GAPDH ratio and presented in arbitrary units (a.u.). All laboratory measurements were made blind to participants' disease status, with samples randomly distributed for analysis.
Plasma adiponectin and leptin determinations
Plasma levels of adiponectin and leptin were analyzed in duplicate using commercially available human high-sensitivity enzyme-linked immunosorbent assay kits (SPI-bio, Montigny le Bretonneux, France; and R&D Systems, Inc., Minneapolis, MN, USA, respectively). The lowest limits of sensitivity were 0.5 ng ml -1 for adiponectin and 7.8 pg ml -1 for leptin, and the intra-and inter-assay variance coefficients were lower than 10%.
Western blot analysis
In all, 100-150 mg of EAT and SAT were rinsed in 5 ml of phosphate saline solution containing 0.5 mM EDTA, 5 mM KCl, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic (HEPES) acid, 2 mM MgCl 2 , 10 mM NaHCO 3 , 0.5 mM KH 2 PO 4 , 0.5mM NaH 2 PO 4 , 10 mM glucose, 110 mM NaCl and 0.16 mM CaCl 2 at pH ¼ 7.4, and then centrifuged at 300 g for 1 min to remove residual blood. Tissues were resuspended (weight/volume) in a lysis buffer (125 mM Tris pH 6.8, 10% glycerol, 2% SDS, 100 mM dithiothreitol, 1 Â anti-protease cocktail from Sigma-Aldrich, St Louis, MO, USA) and sheared by homogenizer pestle using sample grinding kit (GE Healthcare, Waukesha, WI, USA). Then, the proteins were precipitated with 20% trichloroacetic acid in acetone. Finally, samples were resuspended at a final concentration of 1 mg of homogenized tissue per 1 ml in Laemmli buffer. Protein separation (40 ug) was carried out in 12% SDS-polyacrylamide gel electrophoresis gel and transferred on a polyvinylidene fluoride membrane for 45 min at 280 mA. Membranes were blocked for 2 h at room temperature with 5% of milk in Tris-buffered saline tween-20 containing 20 mM Tris-HCl (pH 7.6), 150 mM NaCl and 0.1% Tween 20. The membranes were then exposed with goat adiponectin antibody (1:500 dilution) and goat GAPDH antibody (1:1000) (Santa Cruz Biotechnology, Delaware, CA, USA) overnight, and then to peroxidase-conjugated rabbit anti-goat IgG. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Ltd, London, UK) and quantified by densitometry Image J software. Adiponectin protein levels were evaluated in duplicate and quantified with respect to GAPDH.
Statistical analysis
Categorical variables are expressed as percentages and compared using w 2 -test or Fisher's exact test. We used the Kolmogorov-Smirnov test to check the normality of continuous variables. Non-skewed variables are summarized as the mean (standard deviation) and those with skewed distribution as the median (interquartile range).
Differences between continuous variables were tested for statistical significance by means of Student's t-test. Mann-Whitney test was performed whenever nonparametrical testing was required.
To discard the influence of sex, CAD, hypertension (HT) and statin treatment, we stratified the sample for these variables and repeated the described analysis across strata.
Logistic regression models including possible confounders were used to assess the association between EAT and SAT adiponectin and leptin mRNA levels and diabetes or impaired fasting glucose.
In case of missing data, we checked that there was no unequal distribution between groups.
Statistical significance was defined as Po0.05. All analyses were computed using SPSS 15.0 software for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics
In all, 45 diabetic patients and 75 nondiabetic western European subjects were included in this study. The prevalence of diabetes was almost 38% in our sample. Table 1 presents the main characteristics of the study sample. Mean age was 70.1 years (s.d. 7.7).
Diabetic and nondiabetic groups did not differ significantly for most clinical variables. There was a very high prevalence of obesity in both groups, with overall ratios of overweight and obesity of 55 and 30%, respectively. As for other comorbidities, such as HT and heart failure, the prevalence was higher in the diabetic group, though not significant. CAD was more prevalent in the group of diabetics, with borderline statistical significance.
Concerning drug intake, there were only slight differences in calcium channel blocker consumption, higher in the group of diabetics, and differences in statin consumption, more prevalent in the same group. In all, 24 diabetic patients were on oral antidiabetic agents, mostly sulfonylureas (n ¼ 14) or metformin (n ¼ 8), alone or in combination.
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Fasting glucose levels were higher in the group of diabetics, despite treatment. Diabetic patients had lower cholesterol levels than the nondiabetic group, though the difference was not statistically significant.
EAT and SAT adipokine mRNA expression in diabetic vs nondiabetic subjects Diabetic patients had similar EAT and SAT mRNA adiponectin ( Figure 1 ) and leptin ( Figure 2 ) levels than nondiabetic patients. We stratified the sample according to sex and CAD, but no significant differences were found concerning adiponectin (Table 2 ) and leptin (Table 3 ) mRNA expression in different strata when comparing diabetic and nondiabetic groups. Further stratification for statin consumption or HT led to similar results (data not shown). Conversely, statin treatment did not show a significant effect on adipokine expression in any stratum. As regards the influence of oral antidiabetic drug on EAT and SAT adipokine expression, no significant difference was found when compared with the group of diabetics free from this treatment (EAT adiponectin 14.5 (2.6) vs 14.0 (5.9) a.u., P ¼ 0.68; EAT leptin 9.2 (8.3-10.7) vs 9.6 (7.6-10.8) a.u., P ¼ 0.96; SAT adiponectin 15.3 (5.4) vs 15.7 (4.1) a.u., P ¼ 0.83; SAT leptin 8.9 (7.7-12.6) vs 10.4 (8.6-11.6) a.u., P ¼ 0.77). It should be noted that only one patient was on thiazolidinediones, and therefore the influence of this treatment could not be studied.
Besides, logistic regression models including possible confounders such as gender, age, body mass index, total cholesterol, HT and CAD failed to show EAT and SAT adiponectin and leptin mRNA expression differences in the group of patients with diabetes mellitus or abnormal fasting glucose compared with the control group, as shown in Table 4 .
EAT and SAT adiponectin protein levels in diabetic vs nondiabetic subjects We performed western blot analyses in a subsample of patients (five diabetic and five nondiabetic patients). We did not find significant differences in adiponectin protein expression between both groups, as shown in Table 1 , although a slight trend can be observed toward lower protein levels in SAT in nondiabetic subjects.
Plasma adiponectin and leptin concentrations in diabetic vs nondiabetic subjects Small subsamples of patients were studied to assess differences in plasma adiponectin (n ¼ 12) and leptin levels (n ¼ 26) between diabetic and nondiabetic subjects ( Table 1) . As expected, diabetic patients presented lower adiponectin plasma levels when compared with nondiabetic subjects. However, no significant differences were found in leptin levels, possibly because of the small sample size.
Discussion
This study, based on the largest series of EAT reported, is the first to show that EAT and SAT adiponectin and leptin levels are similar in patients with established diabetes or abnormal fasting glucose as compared with nondiabetic subjects with normal fasting glucose, irrespective of sex, age and other possible confounders. This finding adds complexity to the controversial body of evidence showing that lower plasma Adipose tissue adipokines and diabetes E Teijeira-Fernandez et al adiponectin levels and higher plasma leptin levels are associated with metabolic and cardiovascular conditions. Previous prospective investigations showed a very narrow association between hypoadiponectinemia and the development of insulin resistance 12 and diabetes, 11,13-15 strongly suggesting a relevant role for this adipokine in the physiopathology of diabetes. Laboratory research also resulted in promising conclusions, reinforcing the role of adiponectin as an insulin sensitizer antidiabetic hormone. 7 In this line, consistent with previous research, 10 and even though the subsample analyzed was small, we found that patients with diabetes present significantly lower adiponectin plasma levels as compared with those without diabetes, despite expressing similar adipose tissue mRNA levels. Factors other than adiponectin expression from these fat depots can obviously influence plasma levels. Non-diabetes Diabetes EAT leptin/GAPDH mRNA (a.u.) 
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Curiously, though a beneficial antiatherogenic effect of adiponectin was initially observed, recent studies showed that in patients with CAD higher adiponectin levels are associated with increased risk of cardiovascular events and of cardiovascular and non-cardiovascular mortality. 33 An explanation postulated for this apparent paradox is that adiponectin concentrations are elevated in a counterregulatory manner as a mechanism of response to excessive proatherosclerotic processes. 34 In this scenario, high adiponectin levels would not result in net beneficial effects. It is likely that in patients with diabetes there is also counterregulation of adiponectin expression in visceral adipose tissue and SAT. This mechanism would be intense enough to equal the visceral adipose tissue and SAT adiponectin expression levels with those of nondiabetic patients, as we find in this study. Another plausible explanation that can overlap the latter is that in this set of elderly obese patients, insulin resistance is possibly highly prevalent even in nondiabetic subjects. To minimize this limitation, we also conducted logistic regression analyses and defined diabetes or abnormal fasting glucose as a dependent variable. Again, no statistically significant differences concerning adipokine expression were found.
A recent study showed an association between EAT thickness and impaired glucose tolerance. 35 Differences in the size of fat pads between diabetic and nondiabetic patients might well be one of the reasons why, despite similar adiponectin and leptin expression levels, plasma levels differ between both groups. 10 Although EAT is relatively small in size, it is a representative of visceral adipose tissue 36 and its anatomical location suggests a major role in the physiology and physiopathology of cardiovascular diseases. Our group showed lower EAT adiponectin levels in patients with more severe established CAD, 6 in line with previous observations. 37 Very interestingly, adiponectin levels were decreased in EAT but not in SAT, suggesting a major implication of EAT in the physiopathology of coronary atherosclerosis and CAD. EAT would then act as an endocrine organ directly affecting the underlying coronary arteries. In accordance with previous findings reported, 6 ,31 women and non-CAD individuals express higher EAT adiponectin and leptin levels. We also described an association between lower EAT adiponectin expression levels in patients with HT, but similar SAT levels. 5 SAT could be less involved in the physiopathology of HT than EAT, and very likely a lack of counter-regulation in EAT adiponectin expression could occur in HT.
In this study, we do not find differences in EAT and SAT leptin expression in diabetics with respect to nondiabetic subjects. Prospective studies focused on plasma levels showed a higher rate of development of diabetes in patients with higher baseline leptin levels. 20 We did not find significant differences in leptin plasma levels between diabetic and nondiabetic patients either, but the subsample analyzed was too small to draw any conclusion. Adipose tissue adipokines and diabetes E Teijeira-Fernandez et al
However, concerning leptin and atherosclerosis, laboratory and epidemiological research led to heterogeneous results, [20] [21] [22] [23] [24] 26 suggesting a very complex regulation of the synthesis and secretion of this hormone. Metabolic changes in patients with diabetes might be responsible for the regulation of leptin expression by EAT and SAT.
As for the effect of treatment on adiponectin and leptin expression, only statins and obviously oral antidiabetic agents were differently distributed in diabetic and nondiabetic groups. No relevant trends were observed regarding adipokine expression. The similar adiponectin expression levels in patients under statin treatment, though requiring confirmation by larger studies specifically designed for this purpose, can seem controversial. Statins could have a slight effect, not strong enough to increase adiponectin expression and to decrease leptin expression in this set of patients. Or maybe they could have post-transcriptional rather than transcriptional effects. However, should this be correct, adipokine expression levels would probably change as a result of feedback stimulation. Previous studies focused on the effect of statins on insulin sensitivity and adipokine levels are controversial, not allowing any definite reliable conclusions. [38] [39] [40] [41] [42] It would have been very interesting to check the effect of peroxisome proliferator-activated receptor PPAR-g inhibitors thiazolidinediones on EAT and SAT adipokine levels, but only one patient was taking them, as the use of these drugs is very limited in our area. Other oral antidiabetic drugs do not seem to have significant effects on EAT and SAT adipokine levels.
Inflammatory cytokines, together with leptin and adiponectin, have a crucial role in the pathogenesis of metabolic and cardiovascular diseases. We are starting to understand the importance of these hormones, but their intricate relationship and their accurate effects remain still unclear.
Study limitations
This study follows a cross-sectional design, and hence cannot explain causality but only association between variables. Owing to obvious ethical concerns, only patients undergoing elective heart surgery were included in the study. This is the reason why the mean age of the sample is quite high.
We assessed fasting glucose impairment but oral glucose tolerance test was not routinely applied, and therefore it was not possible to study the whole spectrum of clinical glucose disturbances. This is especially important in the case of CAD patients, as almost one-third can present with IGT. 43, 44 However, differences in adipokine expression
were not found in non-CAD patients, whose prevalence of undiagnosed abnormal glucose regulation is presumably very low. We mostly focused on EAT and SAT mRNA expression levels rather than on protein tissue levels, as the latter could have a different origin and not reflect adipose tissue adiponectin and leptin production properly. In any case, no differences were found in adiponectin protein levels between diabetic and nondiabetic patients in the small subsample studied. Leptin protein levels were not determined.
Overall, we consider that the findings of this study are still fully valid, especially on the basis of an elderly population.
Conclusions
EAT and SAT adiponectin and leptin mRNA levels do not differ between diabetic and nondiabetic patients. Counterregulatory mechanisms of adiponectin and leptin expression in patients with diabetes might partly account for these findings. Adipose tissue adipokines and diabetes E Teijeira-Fernandez et al
